MarkGeyerMD

PubMed

• Universal germline genetic testing in patients with hematologic malignancies using DNA isolated from nail clippings.
  Ozge Ceyhan-Birsoy, Elise Fiala, Satshil Rana, Margaret Sheehan, Jennifer Kennedy, Zarina Yelskaya, Vikas Rai, Yirong Li, Ciyu Yang, Donna Wong, Ivelise Rijo, Jacklyn ...> ;Haematologica. 2024 Apr 4
• Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel.
  Anthony J Perissinotti, Michael R Bishop, Joseph Bubalo, Mark B Geyer, Amy Goodrich, Scott C Howard, Julianna Kula, Sreedhar Mandayam, Mitchell S Cairo, Ching-Hon Pui> ;Cancer Treatment Reviews. 2023 Nov 1
• Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab.
  Rose Parisi, Emily A Cowen, Stephanie Gu, Stephen Dusza, Melissa Pulitzer, Mark B Geyer, Amber C King, Alina Markova> ;Leukemia & Lymphoma. 2023 Sep 1
• 5 citations
  Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia.
  Joseph G W McCarter, David Nemirovsky, Christopher A Famulare, Noushin Farnoud, Abhinita S Mohanty, Zoe S Stone-Molloy, Jordan Chervin, Brian J Ball, Zachary D Epstein...> ;Blood Advances. 2023 Sep 12
• 7 citations
  Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.
  Michael J Mauro, Timothy P Hughes, Dong-Wook Kim, Delphine Rea, Jorge E Cortes, Andreas Hochhaus, Koji Sasaki, Massimo Breccia, Moshe Talpaz, Oliver Ottmann, Hironobu ...> ;Leukemia. 2023 May 1
• 8 citations
  Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.
  Syed S Mahmood, Peter A Riedell, Stephanie Feldman, Gina George, Stephen A Sansoterra, Thomas Althaus, Mahin Rehman, Elena Mead, Jennifer E Liu, Richard B Devereux, Jo...> ;European Heart Journal. 2023 Jun 9
• 3 citations
  Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal.
  Mark B Geyer, Brian C Shaffer, Bhavana Bhatnagar, Alice S Mims, Victoria Klein, Deepika Dilip, Jacob L Glass, Gerard Lozanski, Hani Hassoun, Heather Landau, Yanming Zh...> ;Blood Advances. 2023 Jul 11
• 2 citations
  Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.
  Maximilian Stahl, Andriy Derkach, Noushin Farnoud, Jan Philipp Bewersdorf, Troy Robinson, Christopher Famulare, Christina Cho, Sean Devlin, Kamal Menghrajani, Minal A ...> ;American Journal of Hematology. 2023 Jan 1
• 21 citations
  NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022.
  Elizabeth A Griffiths, Vivek Roy, Laura Alwan, Kimo Bachiashvili, John Baird, Rita Cool, Shira Dinner, Mark Geyer, John Glaspy, Ivana Gojo, Ashley Hicks, Avyakta Kalla...> ;Journal of the National Comprehensive Cancer Network. 2022 May 1
• 9 citations
  Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab.
  Kitsada Wudhikarn, Amber C King, Mark B Geyer, Mikhail Roshal, Yvette Bernal, Boglarka Gyurkocza, Miguel-Angel Perales, Jae H Park> ;Blood Advances. 2022 Mar 8
• 54 citations
  Phase II biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
  Alison J. Moskowitz, Paola Ghione, Eric D. Jacobsen, Jia Ruan, Jonathan H. Schatz, Sarah J. Noor, Patricia L. Myskowski, Santosha A. Vardhana, Nivetha Ganesan, Helen H...> ;Blood. 2021 Oct 19
• 36 citations
  Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy
  Kitsada Wudhikarn, Jessica Flynn, Isabelle Riviere, Mithat Gonen, Xiuyan Wang, Brigitte Senechal, Kevin J. Curran, Mikhail Roshal, Peter Maslak, Mark B. Geyer, Elizabe...> ;Blood. 2021 Aug 19
• 12 citations
  Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing.
  Xiuyan Wang, Oriana Borquez-Ojeda, Jolanta Stefanski, Fang Du, Jinrong Qu, Jagrutiben Chaudhari, Keyur Thummar, Mingzhu Zhu, Ling-bo Shen, Melanie Hall, Paridhi Gautam...> ;Molecular Therapy. Methods & Clinical Development. 2021 Jul 16
• 4 citations
  Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality.
  Maximilian Stahl, Varun Narendra, Justin Jee, Andriy Derkach, Molly Maloy, Mark B Geyer, Anthony R. Mato, Lindsey E. Roeker, Martin S. Tallman, Gunjan L. Shah, Anthony...> ;Leukemia & Lymphoma. 2021 Jun 28
• 7 citations
  Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia.
  Ryan J. Daley, Sridevi Rajeeve, Charlene C. Kabel, Jeremy J. Pappacena, Sarah E. Stump, Jessica A. Lavery, Martin S. Tallman, Mark B. Geyer, Jae H. Park> ;Leukemia & Lymphoma. 2021 Jan 2
• 22 citations
  Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philade...
  Mark B. Geyer, Ellen K. Ritchie, Arati V. Rao, Shreya Vemuri, Jessica Flynn, Meier Hsu, Sean M. Devlin, Mikhail Roshal, Qi Gao, Madhulika Shukla, Jose M. Salcedo, Pete...> ;Haematologica. 2020 Oct 13
• 219 citations
  Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
  , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Blood. 2020 Sep 3
• 26 citations
  Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic.
  Elizabeth A. Griffiths, Laura M Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter T. Curtin, Mark B. Geyer, Ivana Gojo, Avyakta Kallam, Wajih Zaheer Kidwai, Dwigh...> ;Journal of the National Comprehensive Cancer Network. 2020 Sep 1
• 4 citations
  FGFR1 Rearrangement Guides Diagnosis and Treatment of a Trilineage B, T, and Myeloid Mixed Phenotype Acute Leukemia.
  Ying Liu, Xiaoli Mi, Ramya Gadde, Qi Gao, Wenbin Xiao, Yanming Zhang, Rayma Benayed, Maria E. Arcila, Ahmet Dogan, Mark B. Geyer, Mikhail Roshal> ;JCO Precision Oncology. 2020 Aug 25
• 44 citations
  Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents.
  Lindsey E. Roeker, Peter Dreger, Jennifer R. Brown, Oscar B Lahoud, Toby A. Eyre, Danielle M. Brander, Alan P Skarbnik, Catherine C. Coombs, Haesook T. Kim, Matthew S....> ;Blood Advances. 2020 Aug 25
• 1 citations
  Hypofibrinogenemia and disseminated intravascular coagulation rarely complicate treatment-naïve acute lymphoblastic leukemia.
  Charles Gaulin, Angela Chan, Andriy Derkach, Jae H. Park, Simon Mantha, Mark B. Geyer, Martin S. Tallman> ;Leukemia & Lymphoma. 2020 May 18
• 55 citations
  BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy
  Eric L. Smith, Sham Mailankody, Mette Staehr, Xiuyan Wang, Brigitte Senechal, Terence J. Purdon, Anthony F. Daniyan, Mark B. Geyer, Aaron D Goldberg, Elena Mead, Bianc...> ;Cancer Immunology Research. 2019 Jul 1
• 12 citations
  Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia.
  Wenbin Xiao, Aaron D Goldberg, Christopher Famulare, Sean M. Devlin, Nghia T. Nguyen, Sinnifer Sim, Charlene C. Kabel, Minal Patel, Erin McGovern, Akshar Patel, Jessic...> ;Haematologica. 2019 Jul 1
• 63 citations
  Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
  Mark B. Geyer, Isabelle Riviere, Brigitte Senechal, Xiuyan Wang, Yongzeng Wang, Terence J. Purdon, Meier Hsu, Sean M. Devlin, M. Lia Palomba, Elizabeth Halton, Yvette ...> ;JCI Insight. 2019 May 2
• 46 citations
  Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual diseas...
  Amber C. King, Jeremy J. Pappacena, Martin S. Tallman, Jae H. Park, Mark B. Geyer> ;Leukemia Research. 2019 Apr 1
• Join now to see all

Abstracts/Posters

• Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL...
  Mark B. Geyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients
  Mark B. Geyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Pegaspargase Can Safely be Administered in Adults Age 40 and Older with Acute Lymphoblastic Leukemia
  Mark B. Geyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma
  Mark B. Geyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Inotuzumab Ozogamicin Is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High-Risk Molecular Features, Including TP53 Loss
  Mark B. Geyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL...
  Mark B. Geyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all